文献速递头颈外科咽喉与嗓音

部分喉放疗与全喉放疗治疗临床T1-2N0M0/Tis喉癌的比较

Partial vs Whole Laryngeal Radiotherapy for Clinical Stage T1-2N0M0/Tis Laryngeal Carcinoma.
PubMed 文献 · JAMA Otolaryngol Head Neck Surg · 2025-01-01

单机构回顾性队列研究纳入233例T1-2N0M0/Tis喉鳞癌患者,比较部分喉放疗(PLRT,57例)与全喉放疗(WLRT,176例)的疗效与毒性。两组3年局部区域控制、无喉切除生存、无远处转移生存及总生存无重要临床差异,PLRT组急性吞咽困难发生率更低(73.7% vs 92.6%)。置信区间宽,比较有效性存在不确定性。

要点

  • PLRT与WLRT的3年局部区域控制率分别为85.4%和90.8%,差异无重要临床意义。
  • PLRT组急性吞咽困难发生率显著低于WLRT组(73.7% vs 92.6%)。
  • T2肿瘤中WLRT的3年局部区域控制率高于PLRT(85.1% vs 66.7%),但置信区间宽。

核心结论

  • PLRT与WLRT在局部区域控制上未观察到重要临床差异,但PLRT可能与较低的急性毒性相关。
  • 所有终点的宽置信区间表明比较有效性存在实质性不确定性。

研究设计与样本

  • 单机构回顾性队列研究,纳入2013年1月至2024年12月接受调强放疗的233例临床T1-2N0M0/Tis喉鳞癌患者,其中WLRT 176例、PLRT 57例。
  • WLRT组中位随访60(28-87)个月,PLRT组31(16-64)个月;数据分析于2025年1月至2月进行。

主要发现

  • 3年局部区域控制率PLRT 85.4% vs WLRT 90.8%,率差-5.4%(95%CI -13.5%至6.9%)。
  • 3年无喉切除生存率PLRT 93.2% vs WLRT 94%,率差-0.8%(95%CI -9.1%至7.5%)。
  • 3年无远处转移生存率PLRT 100% vs WLRT 97.6%,率差2.4%(95%CI -0.3%至4.9%)。
  • 3年总生存率PLRT 91.4% vs WLRT 88.9%,率差2.5%(95%CI -6.8%至12.8%)。
  • PLRT组无对侧声带失败;T2肿瘤3年局部区域控制率WLRT 85.1% vs PLRT 66.7%,差18.4%(95%CI -5.8%至21.3%)。

关键数值与推荐

  • 急性吞咽困难发生率PLRT 73.7% vs WLRT 92.6%,差异18.9%(95%CI 6.9%至30.9%)。
  • 放疗后3个月MD Anderson吞咽困难量表综合评分PLRT 86 vs WLRT 77,差异8(95%CI 2至14);6个月PLRT 96 vs WLRT 81,差异4(95%CI -2至8)。
  • WLRT组中T1b和Tis病变的肿瘤分期相关差异最大,绝对差50%(95%CI 25.4%至73.2%)。

临床怎么用

  • 对于临床T1-2N0M0/Tis喉癌,PLRT可作为减少急性吞咽困难的放疗策略选择。
  • T2肿瘤选择PLRT需谨慎,因WLRT的3年局部区域控制率数值上更高但置信区间宽。
  • 需结合患者分期、随访条件和毒性风险个体化选择PLRT或WLRT。

局限性

  • 单机构回顾性设计,未调整混杂因素。
  • PLRT组中位随访时间较短,限制晚期毒性和长期肿瘤控制评估。
  • 所有终点置信区间宽,比较有效性存在实质性不确定性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The current standard treatment for clinical tumor stage 1 to 2 or in situ laryngeal carcinoma without node involvement or metastases (T1-2N0M0/Tis) is whole laryngeal radiotherapy (WLRT), whereas microsurgery typically resects only the tumor-involving vocal cord with a narrow margin. Clinical outcomes of partial laryngeal radiotherapy (PLRT) have not been quantified. OBJECTIVE: To compare the effectiveness and toxic effects of PLRT vs WLRT in patients with clinical stage T1-2N0/Tis laryngeal carcinoma. DESIGN, SETTING, AND PARTICIPANTS: This was a single-institution retrospective cohort study of patients with clinical stage T1-2N0M0/Tis squamous cell carcinoma of the larynx who underwent intensity-modulated RT from January 2013 to December 2024. Data were analyzed from January to February 2025. MAIN OUTCOMES AND MEASURES: Long-term locoregional control, laryngectomy-free survival, distant metastasis, and overall toxic effects. Acute and late radiation toxic effects were graded using Common Terminology Criteria for Adverse Events, version 4.0. Patient-reported swallowing-related quality of life (MD Anderson Dysphagia Inventory) was collected at each visit when feasible. RESULTS: The analyses included 233 consecutive patients with T1-2N0M0/Tis squamous cell carcinoma of the larynx who were treated with intensity modulated radiotherapy (176 with WLRT vs 57 with PLRT). The median (IQR) follow-up in the WLRT group was 60 (28-87) months, and in the PLRT group, 31 (16-64) months. The largest tumor stage-related difference in WLRT was observed in T1b (100%) and Tis (50%) disease, with an absolute difference of 50% (95% CI, 25.4% to 73.2%). There were no important clinical differences between PLRT and WLRT in 3-year locoregional control rates (85.4% vs 90.8%; rate difference, -5.4%; 95% CI, -13.5% to 6.9%), laryngectomy-free survival (93.2% vs 94%; rate difference, -0.8%; 95% CI, -9.1% to 7.5%), distant metastasis-free survival (100% vs 97.6%; rate difference, 2.4%; 95% CI, -0.3% to 4.9%), and overall survival (91.4% vs 88.9%; rate difference, 2.5%; 95% CI, -6.8% to 12.8%). There was no contralateral vocal-fold failure in the PLRT group. There was a large difference in the 3-year locoregional control in T2 tumors between the WLRT (85.1%) and PLRT groups (66.7%), with a difference of 18.4% (95% CI, -5.8% to 21.3%). The incidence of acute dysphagia was lower in the PLRT than in the WLRT group (73.7% vs 92.6%; difference, 18.9%; 95% CI, 6.9% to 30.9%). Median composite scores on the MD Anderson Dysphagia Inventory at 3 and 6 months postradiotherapy were higher in the PLRT group (86 vs 77; difference, 8; 95% CI, 2 to 14; and 96 vs 81; difference, 4; 95% CI, -2 to 8; respectively), although the observed differences may not be clinically important. CONCLUSIONS AND RELEVANCE: This cohort study found that there were no clinically important differences observed in locoregional control between PLRT and WLRT; however, PLRT may be associated with lower rates of acute toxic effects compared to WLRT. Wide confidence intervals across all end points indicated substantial uncertainty regarding comparative effectiveness. The shorter median follow-up time in the PLRT group limited evaluation of late toxic effects and long-term tumor control outcomes; together with the lack of adjustment for confounding factors, this study underscores the need for further evaluation of PLRT.

来源:JAMA Otolaryngol Head Neck Surg,查看原文。版权归原作者所有。

引用

  1. Treechairusame T, Dee EC, Cao C, et al. Partial vs Whole Laryngeal Radiotherapy for Clinical Stage T1-2N0M0/Tis Laryngeal Carcinoma. JAMA Otolaryngol Head Neck Surg. 2025. PMID: 41037280. doi:10.1001/jamaoto.2025.3214

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。